Apremilast could lower cardiometabolic risk in psoriasis patients
BOSTON — Psoriasis patients treated with apremilast saw a reduction in subcutaneous and visceral fat, indicating a possible decline in cardiometabolic risk, according to a presentation at the American Academy of Dermatology Annual Meeting.“We know our patients have an increased risk of obesity, an increased risk of dyslipidemia and an increased risk of diabetes, but on top of that,